Wai Conrad sold $111K of CLOV

Wai Conrad (CEO, Counterpart Health) sold 23,627 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.68 ($0.11M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wai Conrad
Published Oct 19, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
high confidence
Mentioned
$CLOV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The modest size of the sale is unlikely to move the stock significantly, but it adds to the flow of insider activity that traders monitor for sentiment cues.

02

Market read

A small insider sale; limited immediate trading relevance but useful for monitoring insider sentiment.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: post‑market filing on Oct 19

Background

Form 4 filings provide transparent insight into insider transactions. CLOV's CEO executed a pre‑arranged 10b5‑1 sale of roughly $110K.

Company-level read

Ticker impact

$CLOVBearishHigh confidence
Context

CEO Wai Conrad sold 23,627 shares for $110.6K via a 10b5‑1 plan, reducing his stake to 1,042,072 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Form 4 is a primary disclosure; the transaction size is small relative to market cap, but CEO sales often prompt short‑term downside bias.

Market effects

Minimal impact on the health‑tech sector.

No broader regional effect.

Limited to CLOV shareholders.

Counterpoint

The sale could be routine under a pre‑arranged plan and not reflect negative fundamentals.

Key entities

  • Wai Conrad

    CEO of Clover Health Investments, reporting a sale of 23,627 shares.

  • Clover Health Investments, Inc.

    Health‑tech firm listed on NASDAQ under ticker CLOV.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.